

Miguel Coelho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4315109/miguel-coelho-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

4,232
citations

29
h-index

64
g-index

97
ext. papers

5,115
ext. citations

4.4
avg, IF

5.03
L-index

#	Paper	IF	Citations
89	Letter to the Editor.. <i>Journal of Paediatrics and Child Health</i> , 2022 ,	1.3	0
88	Profile of cognitive impairment in late-stage Parkinson's disease.. <i>Brain and Behavior</i> , 2022 , e32537	3.4	0
87	Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. <i>Journal of Personalized Medicine</i> , 2022 , 12, 813	3.6	0
86	High frequency of psychosis in late-stage Parkinson's disease.. <i>Clinical Parkinsonism & Related Disorders</i> , 2021 , 5, 100119	0.9	0
85	Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021 , 12, 652424	4.1	0
84	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 661461	5.7	3
83	Sighs during sleep in multiple system atrophy. <i>Sleep Medicine</i> , 2021 , 78, 75-80	4.6	2
82	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1171-1184	5.3	3
81	Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. <i>Biomolecules</i> , 2020 , 10,	5.9	12
80	The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 531-542	2.2	7
79	The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications. <i>Parkinsonism and Related Disorders</i> , 2020 , 75, 91-96	3.6	14
78	Levodopa response in later stages of Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 160-162	3.6	3
77	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , 2020 , 20, 432	3.1	5
76	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 73-81	3.6	14
75	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
74	International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1248-1266	7	323
73	A rare cause of orofacial dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018 , 50, 122-123	3.6	0

72	Vernet syndrome resulting from varicella zoster virus infection-a very rare clinical presentation of a common viral infection. <i>Journal of NeuroVirology</i> , 2018 , 24, 379-381	3.9	2
71	Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS. <i>Journal of Parkinson & Disease</i> , 2017 , 7, 255-261	5.3	3
70	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 41, 113-117	3.6	12
69	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 737-742	2.2	38
68	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017 , 39, 37-43	3.6	29
67	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson & Disease</i> , 2017 , 7, 491-501	5.3	29
66	Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. <i>Scientific Reports</i> , 2017 , 7, 13713	4.9	46
65	Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 1331-1333	7	3
64	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017 , 8, 432	4.1	31
63	The Natural History of Parkinson's Disease 2017 , 129-137		1
62	Time Perception in Mild Cognitive Impairment: Interval Length and Subjective Passage of Time. <i>Journal of the International Neuropsychological Society</i> , 2016 , 22, 755-64	3.1	9
61	Advanced Parkinson disease patients have impairment in prosody processing. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016 , 38, 208-16	2.1	10
60	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016 , 26, 10-6	3.6	44
59	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016 , 7, 27	4.1	11
58	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016 , 11, e0157852	3.7	29
57	Musician's Dystonia as the Initial Presentation of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 624-625	2.2	1
56	Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 953-9	7	54
55	Suicidal behaviors are very rare in antiparkinsonian drug trials. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1008-9	3.6	1

54	Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona-Lisbon cohort. <i>European Journal of Neurology</i> , 2015 , 22, 305-12	6	29
53	Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. <i>European Journal of Neurology</i> , 2015 , 22, 207-10	6	11
52	Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015 , 22, 540-6	6	62
51	Cognitive Impairment in Fall-Related Studies in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 453-69	5.3	22
50	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 561-7	5.3	11
49	Action verbal fluency in Parkinson's patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2015 , 73, 520-5	1.6	15
48	Facial myokymia and autonomic synkinesis responsive to carbamazepine. <i>Revue Neurologique</i> , 2015 , 171, 88-9	3	0
47	STN-DBS does not change emotion recognition in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 166-9	3.6	17
46	I21 Causes Of Death In A European Huntington's Disease Cohort (registry). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, A64-A65	5.5	1
45	Pure ataxia associated with N-methyl-D-aspartate receptor antibodies. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 568-9	3.6	4
44	STN-DBS does not change emotion recognition in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 564-5	3.6	6
43	Spinal cord astrocytoma mimicking multifocal myelitis. <i>Journal of Spinal Cord Medicine</i> , 2014 , 37, 429-31	1.9	1
42	Epidemiology of Levodopa-Induced Dyskinesia 2014 , 33-50		1
41	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013 , 12, 264-74	24.1	322
40	Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 897-900	3.6	3
39	Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. <i>Movement Disorders</i> , 2013 , 28, 1212-4	7	2
38	Referral to rehabilitation in Parkinson's disease: who, when and to what end?. <i>Arquivos De Neuro-Psiquiatria</i> , 2013 , 71, 967-72	1.6	6
37	Phenotypic variability of familial and sporadic Progranulin p.Gln257Profs*27 mutation. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 335-42	4.3	8

36	Paralytic shellfish poisoning due to ingestion of <i>Gymnodinium catenatum</i> contaminated cockles--application of the AOAC HPLC official method. <i>Toxicon</i> , 2012 , 59, 558-66	2.8	34
35	Late-stage Parkinson disease. <i>Nature Reviews Neurology</i> , 2012 , 8, 435-42	15	138
34	RimabotulinumtoxinB 2012 , 452-462		
33	What motivates Parkinson's disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 667-71	3.6	22
32	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , 2011 , 68, 223-30		73
31	Reply to: Late-stage Parkinson's disease: the Barcelona and Lisbon cohorts. Past phenomenology and today's clinical needs. <i>Journal of Neurology</i> , 2011 , 258, 920-920	5.5	
30	Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?. <i>Movement Disorders</i> , 2011 , 26, 1966-7	7	7
29	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S2-41	7	397
28	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
27	Myeloradiculopathy associated to <i>Schistosoma mansoni</i> . <i>BMJ Case Reports</i> , 2011 , 2011,	0.9	3
26	Convergence of miRNA expression profiling, Synuclein interacton and GWAS in Parkinson's disease. <i>PLoS ONE</i> , 2011 , 6, e25443	3.7	184
25	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 237-42	3.6	108
24	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. <i>Journal of Neurology</i> , 2010 , 257, 1524-32	3.5	89
23	Skin cancer and Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 139-48	7	33
22	Prescribing patterns of antiparkinsonian agents in Europe. <i>Movement Disorders</i> , 2010 , 25, 1053-60	7	18
21	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010 , 25, 2604-12	7	155
20	Therapeutic interventions for symptomatic treatment in Huntington's disease. <i>The Cochrane Library</i> , 2009 , CD006456	5.2	67
19	Therapeutic interventions for disease progression in Huntington's disease. <i>The Cochrane Library</i> , 2009 , CD006455	5.2	33

18	Reversible iatrogenic subacute cerebellar syndrome, myoclonus and MRI findings following metronidazole administration. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	8
17	Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 1412-3	5.5	8
16	Treatment options for non-motor symptoms in late-stage Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 523-35	4	12
15	Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2008 , 31, 2-18	1.4	25
14	Botulinum toxin type-B improves sialorrhea and quality of life in bulbar-onset amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2008 , 255, 545-50	5.5	40
13	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1093-9	7	168
12	The management of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 129-40	4	14
11	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. <i>Movement Disorders</i> , 2007 , 22, 1194-201	7	66
10	Skin cancers and precancerous lesions in Parkinson's disease patients. <i>Movement Disorders</i> , 2007 , 22, 1471-1475	7	15
9	Therapeutic interventions for symptomatic treatment in Huntington's disease 2007 ,		1
8	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 809-15	7	83
7	Left hemibody myoclonus due to anomalous right vertebral artery. <i>Movement Disorders</i> , 2005 , 20, 72-5	7	3
6	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005 , 112, 1677-86	4.3	63
5	Bou Rire Prodromique—Reply to a Note. <i>Cerebrovascular Diseases</i> , 2004 , 17, 350-350	3.2	
4	Assessment of time perception: the effect of aging. <i>Journal of the International Neuropsychological Society</i> , 2004 , 10, 332-41	3.1	38
3	Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia. <i>Clinical Neurology and Neurosurgery</i> , 2004 , 106, 129-31	2	8
2	DAT imaging in drug-induced and psychogenic parkinsonism. <i>Movement Disorders</i> , 2003 , 18 Suppl 7, S28-33		88
1	Fou rire prodromique. Case report and systematic review of literature. <i>Cerebrovascular Diseases</i> , 2003 , 16, 101-4	3.2	15

